SCHEMBL25513795

SCHEMBL25513795

CC(C)(C)OC(=O)N1CCCC(S)CC1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.60
EPHX1 P07099 1/20 0.54
RECQL P46063 1/20 0.50
USP2 O75604 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MAPT P10636 2/20 0.48
ALDH1A1 P00352 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
GPR119 Q8TDV5 4/20 0.47
HSD17B10 Q99714 1/20 0.46
KDM4E B2RXH2 1/20 0.46
THRB P10828 1/20 0.46
PTPN2 P17706 1/20 0.46
PTPN1 P18031 1/20 0.46
PTPN6 P29350 1/20 0.46
ABL1 P00519 1/20 0.45
RIN1 Q13671 1/20 0.45
PREP P48147 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2927661 1.00 HPGD (0.60) HPGDEPHX1RECQLUSP2SMN1; SMN2
SCHEMBL1244691 0.93 HPGD (0.58) HPGDEPHX1RECQLUSP2SMN1; SMN2
SCHEMBL2230223 0.87 MEN1 (0.55) HPGDEPHX1RECQLUSP2SMN1; SMN2
SCHEMBL1065990 0.87 MEN1 (0.55) HPGDEPHX1RECQLUSP2SMN1; SMN2
SCHEMBL216322 0.87 MEN1 (0.55) HPGDEPHX1RECQLUSP2SMN1; SMN2
SCHEMBL1335011 0.83 HPGD (0.51) HPGDEPHX1RECQLUSP2SMN1; SMN2
SCHEMBL1334464 0.83 HPGD (0.51) HPGDEPHX1RECQLUSP2SMN1; SMN2
SCHEMBL1334462 0.83 HPGD (0.51) HPGDEPHX1RECQLUSP2SMN1; SMN2
SCHEMBL8269500 0.81 HPGD (0.62) HPGDEPHX1RECQLUSP2SMN1; SMN2
SCHEMBL1096914 0.81 HPGD (0.62) HPGDEPHX1RECQLUSP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250090524-A1 BTK INHIBITORS BIOGEN MA INC. 2025-03-20 US disclosed
CN-118984829-A BTK inhibitors 渤健马萨诸塞州股份有限公司 2024-11-19 CN disclosed
EP-4430048-A1 BTK INHIBITORS Biogen MA Inc. (US) 2024-09-18 EP disclosed
WO-2023086575-A1 BTK INHIBITORS BIOGEN MA INC. (US) 2023-05-19 WO disclosed
WO-2023086575-A1 BTK INHIBITORS BIOGEN MA INC. (US) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250090524-A1 BTK INHIBITORS BTK, SYK, LYN HPGD 3898/4885EPHX1 3433/4885RECQL 1990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.